Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer

Figure 5 Sensitivity analysis of overall survival. A: After propensity score-matching analysis in overall survival (OS) (ratio = 1); B: After propensity score-matching analysis in OS (ratio = 2); C: After propensity score-matching analysis in OS (ratio = 3); D: After inverse probability of treatment weighting analysis (OS); E: Kaplan-Meier curve after excluding 4 patients who received single-agent chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy in OS; F: Kaplan-Meier curve restricting the cohort to irinotecan-based chemotherapy patients in OS.